People Background Check
Find People:

Christopher A Gajda, Age 5611572 Sagewood Dr, Moorpark, CA 93021

Get Report
Known as:
Christopher Andrew Gajda Chris A Gajda
Related to:
Matiana K Gajda 22 Samantha Gajda 24

Christopher Gajda Phones & Addresses

11572 Sagewood Dr, Moorpark, CA 93021 (805) 552-0179

San Diego, CA

6149 Wilson Rd, Ann Arbor, MI 48108 (734) 944-5789

2684 Bellwood Ave, Ann Arbor, MI 48104

Ypsilanti, MI

Ventura, CA

Social networks

Christopher A Gajda

Linkedin

Work

Company: Huya bioscience international Jan 2019 Position: Vice president of program management

Education

Degree: Master of Business Administration, Masters School / High School: University of Michigan Sep 1996 to May 2000 Specialities: Management

Skills

Biotechnology • Pharmaceutical Industry • R&D • Commercialization • Biopharmaceuticals • Drug Discovery • Cross Functional Team Leadership • Lifesciences • Clinical Trials • Oncology • Strategy • Return on Investment • Chemistry • Drug Development • R&D Planning • Mergers

Languages

French

Interests

Children • Education • Environment • Science and Technology • Health

Emails

c***[email protected]

Industries

Pharmaceuticals

Mentions for Christopher A Gajda

Resumes & CV records

Resumes

Christopher Gajda Photo 16

Vice President Of Program Management

Location:
San Diego, CA
Industry:
Pharmaceuticals
Work:
Huya Bioscience International
Vice President of Program Management Arena Pharmaceuticals May 2017 - Jul 2018
Senior Director and Program Leader, Ralinepag Amgen Jun 2015 - Apr 2017
Director, Program Management Lead Amgen Apr 2005 - May 2015
Director, Pipeline Strategy and Portfolio Management Pfizer May 2000 - Nov 2004
Associate Director Warner Lambert May 1993 - May 2000
Scientist
Education:
University of Michigan Sep 1996 - May 2000
Master of Business Administration, Masters, Management University of Toronto Sep 1991 - May 1993
Master of Science, Masters, Organic Chemistry University of Windsor Sep 1987 - May 1991
Bachelors, Bachelor of Science, Biochemistry
Skills:
Biotechnology, Pharmaceutical Industry, R&D, Commercialization, Biopharmaceuticals, Drug Discovery, Cross Functional Team Leadership, Lifesciences, Clinical Trials, Oncology, Strategy, Return on Investment, Chemistry, Drug Development, R&D Planning, Mergers
Interests:
Children
Education
Environment
Science and Technology
Health
Languages:
French

Publications & IP owners

Us Patents

Methods Of Making Dihydropyrone Hiv Protease Inhibitors

US Patent:
6380400, Apr 30, 2002
Filed:
Oct 31, 2000
Appl. No.:
09/674381
Inventors:
Victor Fedij - Holland MI, 49424
Christopher Andrew Gajda - Ann Arbor MI, 48104
Brian Keith Huckabee - Holland MI, 49424
Brian Stuart Moon - Holland MI, 49424
Kenneth Thomas Porter - Holland MI, 49424
Denis Martin Sobieray - Holland MI, 48424
Timothy Lee Stuk - Holland MI, 49424
Bradley Dean Tait - Canton MI, 48187
James Norton Wemple - Holland MI, 49424
International Classification:
C07D30932
US Classification:
549292, 558234, 558241, 560308
Abstract:
The present invention relates to methods of making dihydropyrone HIV inhibitors.

Hiv Protease Inhibitors

US Patent:
6512006, Jan 28, 2003
Filed:
Aug 17, 2000
Appl. No.:
09/641260
Inventors:
John Michael Domagala - Canton MI
Edmund Lee Ellsworth - Brighton MI
Christopher Andrew Gajda - Ann Arbor MI
Elizabeth Ann Lunney - Ann Arbor MI
Alexander Pavlovsky - Ann Arbor MI
Vara Prasad Venkata Nagendra Josyula - Ann Arbor MI
Bradley Dean Tait - Killingworth CT
Assignee:
Warner-Lambert Company - Ann Arbor MI
International Classification:
C07D30930
US Classification:
514460, 546192, 549292
Abstract:
The present invention related to novel dihydropyrones possessing 3-position nitrogen atom, which inhabit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections, and diseases, including AIDS.

Hiv Protease Inhibitors

US Patent:
6528510, Mar 4, 2003
Filed:
Nov 2, 2000
Appl. No.:
09/674652
Inventors:
John Michael Domagala - Canton MI
Edmund Lee Ellsworth - Brighton MI
Christopher Andrew Gajda - Ann Arbor MI
Susan Elizabeth Hagen - Canton Township MI
Michael James Lovdahl - Ann Arbor MI
Elizabeth Ann Lunney - Ann Arbor MI
Larry James Markoski - Champaign IL
Josyula Venkata Nagendra Vara Prasad - Ann Arbor MI
Bradley Dean Tait - Canton MI
Assignee:
Warner-Lambert Company - Morris Plains NJ
International Classification:
A61K 31495
US Classification:
51425201, 5142275, 5142521, 514256, 514269, 514314, 514397, 544 60, 544298, 544315, 544374, 546 1, 546268, 5483044, 5483047, 5483111, 549 29, 549292, 549417
Abstract:
The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

Hiv Protease Inhibitors

US Patent:
6852711, Feb 8, 2005
Filed:
Nov 19, 2002
Appl. No.:
10/299510
Inventors:
John Michael Domagala - Canton MI, US
Edmund Lee Ellsworth - Brighton MI, US
Christopher Andrew Gajda - Ann Arbor MI, US
Susan Elizabeth Hagen - Canton Township MI, US
Michael James Lovdahl - Ann Arbor MI, US
Elizabeth Ann Lunney - Ann Arbor MI, US
Larry James Markoski - Champaign IL, US
Josyula Venkata Nagendra Vara Prasad - Ann Arbor MI, US
Bradley Dean Tait - Canton MI, US
Assignee:
Agouron Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K031/33
A61K031/35
C07D277/00
C07D309/00
C07D315/00
US Classification:
514183, 514359, 514367, 514393, 514412, 514415, 514451, 514460, 548152, 548169, 548178, 5483044, 548509, 549 29, 549292, 549417
Abstract:
The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

Hiv Protease Inhibitors

US Patent:
6927217, Aug 9, 2005
Filed:
Oct 16, 2002
Appl. No.:
10/271467
Inventors:
John Michael Domagala - Canton MI, US
Edmund Lee Ellsworth - Brighton MI, US
Christopher Andrew Gajda - Ann Arbor MI, US
Elizabeth Ann Lunney - Ann Arbor MI, US
Alexander Pavlovsky - Ann Arbor MI, US
Vara Prasad Venkata Nagendra Josyula - Ann Arbor MI, US
Bradley Dean Tait - Killingworth CT, US
Assignee:
Warner-Lambert Company - Ann Arbor MI
International Classification:
C07D401/06
C07D401/04
C07D403/04
A61K031/351
US Classification:
5142278, 5142315, 51425201, 5142541, 514256, 514326, 514336, 514367, 514365, 514372, 514378, 514381, 514383, 514393, 514406, 514444, 514451, 544 60, 544149, 544238, 544333, 544374, 544405, 5462844, 546192, 548152, 548215, 548240, 548255, 5482672, 548254, 5483641, 549 60, 549292
Abstract:
The present invention relates to novel dihydropyrones of Formula I wherein X is NH or NR, which inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS.

Hiv Protease Inhibitors

US Patent:
2005007, Apr 7, 2005
Filed:
Sep 9, 2004
Appl. No.:
10/938442
Inventors:
Frederick Boyer - Canton Township MI, US
John Domagala - Canton MI, US
Edmund Ellsworth - Brighton MI, US
Christopher Gajda - Ann Arbor MI, US
Susan Hagen - Canton Township MI, US
Michael Lovdahl - Ann Arbor MI, US
Elizabeth Lunney - Ann Arbor MI, US
Larry Markoski - Champaign IL, US
Josyula Venkata Prasad - Ann Arbor MI, US
Bradley Tait - Canton MI, US
International Classification:
C07D309/30
A61K031/366
US Classification:
514460000, 514459000, 549293000
Abstract:
The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

Dihydropyrones With Improved Antiviral Activity

US Patent:
5834506, Nov 10, 1998
Filed:
Jun 27, 1997
Appl. No.:
8/883743
Inventors:
Frederick Earl Boyer - Canton Township MI
John Michael Domagala - Canton MI
Edmund Lee Ellsworth - Brighton MI
Christopher Andrew Gajda - Ann Arbor MI
Susan Elizabeth Hagen - Canton Township MI
Harriet Wall Hamilton - Chelsea MI
Elizabeth Ann Lunney - Ann Arbor MI
Larry James Markoski - Ypsilanti MI
Josyula Venkata Nagendra Vara Prasad - Ann Arbor MI
Bradley Dean Tait - Canton MI
Assignee:
Warner-Lambert Company - Morris Plains NJ
International Classification:
A61K 3135
A61K 31415
US Classification:
514460
Abstract:
This invention pertains to improved antiviral activity of 6,6-disubstituted-5,6-dihydropyran-2-ones caused by judicious placement of certain polar substituents at the 3 and/or 6 positions. The same substituents which enhance the cellular activity also diminish cytotoxicity further enhancing the desirable properties of these agents as antivirals.

Dihydropyrones With Improved Antiviral Activity

US Patent:
6046355, Apr 4, 2000
Filed:
Jul 28, 1998
Appl. No.:
9/124190
Inventors:
Frederick Earl Boyer - Canton Township MI
John Michael Domagala - Canton MI
Edmund Lee Ellsworth - Brighton MI
Christopher Andrew Gajda - Ann Arbor MI
Susan Elizabeth Hagen - Canton Township MI
Harriet Wall Hamilton - Chelsea MI
Elizabeth Ann Lunney - Ann Arbor MI
Larry James Markoski - Ypsilanti MI
Josyula Venkata Nagendra Vara Prasad - Ann Arbor MI
Bradley Dean Tait - Canton MI
Assignee:
Warner-Lambert Company - Morris Plains NJ
International Classification:
C07D30931
US Classification:
562 91
Abstract:
This invention pertains to improved antiviral activity of 6,6-disubstituted-5,6-dihydropyran-2-ones caused by judicious placement of certain polar substituents at the 3 and/or 6 positions. The same substituents which enhance the cellular activity also diminish cytotoxicity further enhancing the desirable properties of these agents as antivirals.

Possible Relatives

Jacek Z Gajda  Lee A Gajda  Marek M Gajda  Maria T Gajda  Mary A Gajda  Piotr Gajda  Amy J Gajda  Christopher E Stamps  Christopher L Stancil  Christopher C Standifer 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.